Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

621
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
621
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

6.1K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.1K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

477
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
477
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

14
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

560
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
560

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the impact of gamma-aminobutyric acid on diabetic retinopathy in a large US population-based cohort.

American journal of ophthalmology·2026
Same author

Recombinant Zoster Vaccine Uptake in Patients with Noninfectious Ocular Inflammatory Diseases Receiving Immunosuppression.

American journal of ophthalmology·2026
Same author

Risk Factors for Poor Visual Outcomes Among Males with Idiopathic Intracranial Hypertension (IIH).

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation/Loss in Eyes With Geographic Atrophy.

Ophthalmology·2026
Same author

Demographic and Prevalence Dynamics of Macular Telangiectasia Type 2 From 2015 to 2024.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions.

American journal of ophthalmology·2026

Related Experiment Video

Updated: Jul 18, 2025

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

2.7K

The Incidence, Time to Development, and Risk Factors for Fellow Eye Retinal Vein Occlusions.

Brian J Liu, Jacqueline K Shaia, Kevin Allan

    Ophthalmic Surgery, Lasers & Imaging Retina
    |August 21, 2023
    PubMed
    Summary

    Fellow eye retinal vein occlusion (RVO) affects 3.6% of patients, often within 18 months. Chronic kidney disease and diabetic retinopathy are key risk factors for developing RVO in the other eye.

    More Related Videos

    In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility
    07:35

    In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

    Published on: April 21, 2022

    2.2K
    Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
    12:28

    Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

    Published on: March 12, 2022

    3.7K

    Related Experiment Videos

    Last Updated: Jul 18, 2025

    Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
    07:23

    Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

    Published on: August 6, 2021

    2.7K
    In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility
    07:35

    In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

    Published on: April 21, 2022

    2.2K
    Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
    12:28

    Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

    Published on: March 12, 2022

    3.7K

    Area of Science:

    • Ophthalmology
    • Retinal Vascular Diseases
    • Epidemiology

    Background:

    • Retinal vein occlusion (RVO) is a significant cause of vision loss.
    • Factors influencing the development of RVO in the fellow eye are not well understood.
    • Understanding these factors is crucial for early intervention and prevention.

    Purpose of the Study:

    • To determine the incidence and identify risk factors for fellow eye RVO.
    • To analyze the time course of RVO development in the contralateral eye.
    • To provide insights into the progression of retinal vascular diseases.

    Main Methods:

    • Retrospective case-control study design.
    • Involved comparison between patients with unilateral RVO and those who developed fellow eye RVO.
    • Data collected from 1,083 patients.

    Main Results:

    • Cumulative incidence of fellow eye RVO was 3.6% (95% CI 2.61-4.94).
    • Median time to development of fellow eye RVO was 18 months (95% CI 6.0-28.0).
    • Associated risk factors included chronic kidney disease (OR 3.78) and diabetic retinopathy (OR 3.18).

    Conclusions:

    • Fellow eye RVO is uncommon but typically manifests within the first few years post-diagnosis.
    • Several patient characteristics are significantly associated with the development and timing of fellow eye RVO.
    • These findings highlight the importance of monitoring patients with unilateral RVO for contralateral disease development.